

ForPatients

by Roche

Duchenne Muscular Dystrophy (DMD)

Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

Trial Status
Completed

Trial Runs In
13 Countries

Trial Identifier
NCT03039686
2016-001654-18,WN40227
CN001-016

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).

Hoffmann-La Roche
Sponsor

Phase 2/Phase 3
Phase

NCT03039686 2016-001654-18,WN40227 CN001-016
Trial Identifiers

Eligibility Criteria:

Gender
Male

Age
>=6 Years & <= 11 Years

Healthy Volunteers
No
